2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2300 Radiomic profiling for the non-invasive assessment of intratumoral heterogeneity in multiple myeloma

Guneet Singh Janda, M.D., Michael Howe2, Emmanuel Contreras Guzman3, Jacob Shreve, MD4, Surendra Dasari, Associate Professor5, Saurabh Zanwar, MBBS, MD6, Nadine Abdallah I, MD7, Wilson Gonsalves, MD8, Francis Buadi, MD9, Joselle M Cook, M.D.10, Taxiarchis Kourelis, MD11, Suzanne Hayman, MD12, David Dingli, MD, PhD13, Angela Dispenzieri, MD14, Morie Gertz15, Prashant Kapoor, MD16, Rafael Fonseca, MD17, S. Vincent Rajkumar, MD18, Yi Lin Jr, MD, PhD19, Jason Young, MD20, Matthew Thorpe21, Stephen Broski, MD22, Jansen N Seheult, MBBCh, BAO, MSc, MS, MD23, Nicholas Jeffrey Braun, PhD24, Shaji Kumar, MD25, Moritz Binder, MD, MPH26
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States

Introduction: Multiple myeloma disseminates and evolves over time, with considerable interpatient and intrapatient heterogeneity (Rasche et al. 2022). Absent invasive multisite sampling, assessments of disease biology and measurable residual disease (MRD) rely largely on bone marrow assays. The lack of noninvasive technologies to capture disease complexity in space and time remains a critical barrier to accurate MRD assessment, development of targeted therapies, and understanding of extramedullary disease. Here, we investigate the use of novel image-based biomarkers with lesion-specific resolution to capture this heterogeneity and for prognostic assessment.

Methods: We obtained pretreatment 18F-FDG PET/CT scans from patients with newly diagnosed myeloma along with clinical and laboratory data (Mayo Clinic, 2004-2023 cohort). The native DICOM images of 641 patients with detectable metabolic tumor volume (MTV) were preprocessed and subjected to automated image segmentation (nnU-Net v2.0, inference using a custom-trained hematologic malignancies model, 49±19 minutes per scan). Limitations include variability in image quality and PET reconstruction. Manual quality control of model segmentations was performed. PyRadiomics was used to extract quantitative radiomic features. We evaluated associations of tumor size-, shape-, and texture-related radiomic features with high-risk disease (stage and bone marrow cytogenetics), response to first-line therapy (IMWG criteria), and survival outcomes. Radiomic features were quantile-normalized for downstream modeling. All p values were adjusted for multiple comparisons (Benjamini-Hochberg).

Results: The median age of the 641 patients was 65 years (range, 32-91); 396 patients (62%) were male. There were 4,272 lesions across the 641 patients (median 2 per patient, IQR 1-6), with a median MTV of 28.1 mL (IQR 7.5-117.8). The largest lesion accounted for a median 74% of each patient's total MTV. Within each scan, the three largest lesions reproduced all-lesion MTV-weighted mean radiomics (median ρ=0.99) but incompletely captured interlesion heterogeneity (median ρ=0.70).

Increased gray-level heterogeneity in the three largest lesions (MTV-weighted gray-level non-uniformity) was associated with higher ISS stage (OR 1.20 per IQR, 95% CI 1.11-1.31, p<0.001, n=444). Greater heterogeneity in lesion shape (maximum pairwise shape difference across all lesions) was associated with greater bone marrow involvement (β=4.25 percentage points per IQR, 95% CI 2.81-5.69, p<0.001, n=390). Dominant-lesion gray-level maximum probability was associated with high-risk cytogenetics (OR 1.43 per IQR, 95% CI 1.10-1.85, p=0.007, n=319).

Higher lesion count and MTV were associated with inferior OS (lesion count: HR 1.47 per log-IQR, 95% CI 1.19-1.82, p<0.001; total MTV: HR 1.64 per log-IQR, 95% CI 1.24-2.17, p<0.001; n=246), and both remained significant after adjustment for age, ISS, and high-risk cytogenetics (HR 1.32, 95% CI 1.06-1.64, p=0.014 and HR 1.42, 95% CI 1.07-1.89, p=0.014, respectively).

Greater MTV-weighted gray-level non-uniformity and maximum large-area high-gray-level emphasis were associated with inferior OS (HR 1.04 per IQR, 95% CI 1.02-1.07, p=0.001 and HR 1.02 per IQR, 95% CI 1.00-1.05, p=0.016, respectively; n=246), and both remained significant after adjustment for age, ISS, and high-risk cytogenetics (HR 1.03, 95% CI 1.00-1.06, p=0.041 and HR 1.02, 95% CI 1.00-1.04, p=0.017, respectively).

Greater spatial dissemination (maximum distance between lesions) was associated with inferior PFS after adjustment for age and ISS (HR 1.32 per IQR, 95% CI 1.01-1.72, p=0.039, n=158). Greater heterogeneity in lesion shape (variation in elongation) was associated with lower odds of complete or stringent complete response (CR/sCR) (OR 0.40 per IQR, 95% CI 0.22-0.74, p=0.003, n=174). In five-fold patient-level cross-validation, a ridge-penalized Cox regression model incorporating tumor volume and texture achieved a C-index of 0.71 and mortality AUROCs of 0.72, 0.72, and 0.76 at 2, 3, and 5 years, respectively.

Conclusions: Radiomic profiling of standard-of-care 18F-FDG PET/CT scans enables the capture of disseminated lesions while preserving spatial information. The resulting image-based biomarkers are predictive of key disease characteristics and independently prognostic, supporting lesion-level imaging as a component of a multi-omics framework for understanding multiple myeloma in space and time.

Guneet Singh Janda, M.D.: No relevant conflicts of interest to declare.